MyoKardia, Inc. (MYOK) Reaches $49.60 52-Week High; Last Week Aegean Marine Petroleum Network Inc. (ANW) Coverage

January 11, 2018 - By Darrin Black

Among 5 analysts covering Aegean Marine Petrol (NYSE:ANW), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aegean Marine Petrol had 14 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Aegean Marine Petroleum Network Inc. (NYSE:ANW) has “Neutral” rating given on Thursday, May 25 by Clarkson Capital. Jefferies maintained the shares of ANW in report on Monday, September 18 with “Buy” rating. The stock has “Buy” rating by Jefferies on Monday, December 18. The stock of Aegean Marine Petroleum Network Inc. (NYSE:ANW) earned “Buy” rating by Stifel Nicolaus on Thursday, July 20. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, November 8. The firm has “Buy” rating by Clarksons Platou given on Friday, August 11. The stock of Aegean Marine Petroleum Network Inc. (NYSE:ANW) earned “Buy” rating by Jefferies on Monday, October 23. Jefferies maintained it with “Buy” rating and $800 target in Friday, August 11 report. Jefferies maintained Aegean Marine Petroleum Network Inc. (NYSE:ANW) on Thursday, November 16 with “Buy” rating. Stifel Nicolaus downgraded the shares of ANW in report on Wednesday, May 24 to “Hold” rating. See Aegean Marine Petroleum Network Inc. (NYSE:ANW) latest ratings:

18/12/2017 Broker: Jefferies Rating: Buy New Target: $7.0 Initiate
16/11/2017 Broker: Jefferies Rating: Buy New Target: $7.0 Maintain
08/11/2017 Broker: Stifel Nicolaus Rating: Buy Old Target: $9 New Target: $8 Maintain
23/10/2017 Broker: Jefferies Rating: Buy New Target: $8.0 Maintain
22/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $9.0 Maintain
18/09/2017 Broker: Jefferies Rating: Buy New Target: $8.0 Maintain
11/08/2017 Broker: Jefferies Rating: Buy New Target: $8.0000 Maintain
11/08/2017 Broker: Clarksons Platou Old Rating: Neutral New Rating: Buy Upgrade
20/07/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $9.0000 Maintain

The stock of MyoKardia, Inc. (NASDAQ:MYOK) hit a new 52-week high and has $51.58 target or 4.00% above today’s $49.60 share price. The 5 months bullish chart indicates low risk for the $1.77 billion company. The 1-year high was reported on Jan, 11 by Barchart.com. If the $51.58 price target is reached, the company will be worth $70.92 million more. The stock increased 2.37% or $1.15 during the last trading session, reaching $49.6. About 318,651 shares traded. MyoKardia, Inc. (NASDAQ:MYOK) has risen 11.16% since January 11, 2017 and is uptrending. It has underperformed by 5.54% the S&P500.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $1.77 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

Analysts await MyoKardia, Inc. (NASDAQ:MYOK) to report earnings on March, 12. They expect $-0.40 EPS, down 190.91% or $0.84 from last year’s $0.44 per share. After $-0.42 actual EPS reported by MyoKardia, Inc. for the previous quarter, Wall Street now forecasts -4.76% EPS growth.

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia has $24 highest and $18 lowest target. $21.33’s average target is -57.00% below currents $49.6 stock price. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. The stock of MyoKardia, Inc. (NASDAQ:MYOK) earned “Outperform” rating by BMO Capital Markets on Wednesday, July 20. Wells Fargo initiated the shares of MYOK in report on Friday, December 4 with “Outperform” rating. Credit Suisse initiated the stock with “Outperform” rating in Monday, November 23 report. As per Monday, November 23, the company rating was initiated by Cowen & Co. The rating was initiated by Wedbush with “Outperform” on Monday, November 23.

The stock increased 2.20% or $0.1 during the last trading session, reaching $4.65. About 317,414 shares traded. Aegean Marine Petroleum Network Inc. (NYSE:ANW) has risen 43.45% since January 11, 2017 and is uptrending. It has outperformed by 26.75% the S&P500.

Aegean Marine Petroleum Network, Inc., together with its subsidiaries, operates as a marine fuel logistics firm that markets and supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers worldwide. The company has market cap of $188.98 million. The firm offers fueling services to ocean-going and a range of coastal vessels, including oil tankers, container ships, drybulk carriers, cruise ships, reefers, LNG/LPG carriers, car carriers, and ferries, as well as to marine fuel traders, brokers, and other end-users of marine fuel and lubricants. It has a 13.32 P/E ratio. It also markets and distributes marine lubricants under the Alfa Marine Lubricants brand; and provides a range of shipping services, such as technical support and maintenance, insurance arrangement and handling, financial administration, and accounting services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com